Injection, ramucirumab
Products billed under this code include Cyramza.
Payment limit per 5 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Cyramza.
Payment limit per 5 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Cyramza | Eli Lilly and Company | 00002-7669-01 | 20 | $1,527.96 |
| Cyramza | Eli Lilly and Company | 00002-7678-01 | 100 | $7,639.80 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $76.398 | −$0.167 | 5 MG | Injection, ramucirumab | v1, posted September 17, 2026 |
| 3Q26 | $76.565 | +$1.093 | 5 MG | Injection, ramucirumab | v1, posted September 15, 2026 |
| 2Q26 | $75.472 | −$0.249 | 5 MG | Injection, ramucirumab | v1, posted September 15, 2026 |
| 1Q26 | $75.721 | +$1.362 | 5 MG | Injection, ramucirumab | v1, posted September 15, 2026 |
| 4Q25 | $74.359 | −$0.094 | 5 MG | Injection, ramucirumab | v1, posted September 8, 2026 |
| 3Q25 | $74.453 | +$1.085 | 5 MG | Injection, ramucirumab | v1, posted March 10, 2026 |
| 2Q25 | $73.368 | +$0.456 | 5 MG | Injection, ramucirumab | v1, posted March 10, 2026 |
| 1Q25 | $72.912 | +$1.841 | 5 MG | Injection, ramucirumab | v1, posted December 19, 2025 |
| 4Q24 | $71.071 | −$0.19 | 5 MG | Injection, ramucirumab | v1, posted June 11, 2025 |
| 3Q24 | $71.261 | +$1.608 | 5 MG | Injection, ramucirumab | v1, posted June 11, 2025 |
| 2Q24 | $69.653 | −$0.591 | 5 MG | Injection, ramucirumab | v1, posted March 11, 2025 |
| 1Q24 | $70.244 | +$1.241 | 5 MG | Injection, ramucirumab | v1, posted December 19, 2024 |
| 4Q23 | $69.003 | +$0.133 | 5 MG | Injection, ramucirumab | v1, posted October 10, 2024 |
| 3Q23 | $68.87 | +$2.021 | 5 MG | Injection, ramucirumab | v1, posted June 5, 2024 |
| 2Q23 | $66.849 | −$0.014 | 5 MG | Injection, ramucirumab | v1, posted February 23, 2024 |
| 1Q23 | $66.863 | +$1.243 | 5 MG | Injection, ramucirumab | v1, posted December 6, 2023 |
| 4Q22 | $65.62 | −$0.054 | 5 MG | Injection, ramucirumab | v1, posted June 22, 2023 |
| 3Q22 | $65.674 | +$1.984 | 5 MG | Injection, ramucirumab | v1, posted June 9, 2023 |
| 2Q22 | $63.69 | +$0.133 | 5 MG | Injection, ramucirumab | v1, posted December 14, 2022 |
| 1Q22 | $63.557 | +$0.867 | 5 MG | Injection, ramucirumab | v1, posted June 8, 2022 |
| 4Q21 | $62.69 | +$0.313 | 5 MG | Injection, ramucirumab | v1, posted June 2, 2022 |
| 3Q21 | $62.377 | +$1.008 | 5 MG | Injection, ramucirumab | v1, posted June 2, 2022 |
| 2Q21 | $61.369 | −$0.288 | 5 MG | Injection, ramucirumab | v1, posted March 1, 2022 |
| 1Q21 | $61.657 | – | 5 MG | Injection, ramucirumab | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.